A screen to identify drug resistant variants to target-directed anti-cancer agents

The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid Leukemia (CML)-associated Bcr-Abl kinase, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Azam, Mohammad, Raz, Tal, Nardi, Valentina, Opitz, Sarah L., Daley, George Q.
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC248481/
https://www.ncbi.nlm.nih.gov/pubmed/14615817
http://dx.doi.org/10.1251/bpo63

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC248481/
https://www.ncbi.nlm.nih.gov/pubmed/14615817
http://dx.doi.org/10.1251/bpo63

Ejemplares similares